Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

JQAD1 is a proteolysis-targeting chimera (PROTAC) composed of the p300 and CREB-binding protein (CBP) inhibitor A-485 (Item No. 24119) conjugated to a cereblon (CRBN) ligand.1 It selectively induces the degradation of p300 over CBP in Kelly MYCN-amplified neuroblastoma cells when used at a concentration of 10 µM for 24 hours. JQAD1 (0.5 µM) decreases histone 3 lysine 27 (H3K27) acetylation and induces apoptosis in Kelly cells. In vivo, JQAD1 (40 mg/kg) decreases tumor volume, increases survival, and reduces tumoral p300 but not CBP levels in a Kelly neuroblastoma mouse xenograft model.
WARNING This product is not for human or veterinary use.
1. EP300 selectively controls the enhancer landscape of MYCN-